Molcure announced a multi-year strategic research collaboration with Boehringer Ingelheim to discover and develop innovative antibody therapeutics across multiple targets, utilizing Molcure’s proprietary AI-powered platform.

Therapeutic monoclonal antibodies (mAbs) have become a cornerstone of modern medicine, particularly in oncology, autoimmune disorders, and infectious diseases. While mAbs have already transformed the treatment landscape for millions of patients worldwide, the discovery and development process remains complex, costly, and time-intensive using conventional methods.

This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery to accelerate the identification of novel antibody candidates. Traditional discovery methods have only scratched the surface of the vast antibody design space. By integrating artificial intelligence into the workflow, the two companies aim to significantly expand the range and efficiency of antibody exploration and optimization.

At the core of Molcure’s platform is a proprietary large language model (LLM) specifically engineered for antibody design. Molcure’s AI system is capable of learning from limited data sets and integrating high-throughput experimental data to model and generate novel antibody sequences. This hybrid approach—merging in silico modeling with experimental validation—enables the identification of unique antibody candidates that are often overlooked by conventional techniques.

“We are honored that Boehringer Ingelheim has chosen Molcure as a strategic partner, recognizing the potential of our AI-driven technology to accelerate and enhance antibody discovery,” said Satoshi Tamaki, CEO and CSO of Molcure Inc. “We look forward to working closely with their team to push the boundaries of what's possible in therapeutic antibody development and to bring forward new treatments that improve the lives of patients around the world.”

The partnership supports Boehringer Ingelheim’s mission to deliver first-in-class therapies through scientific innovation. By combining Molcure’s advanced AI capabilities with Boehringer Ingelheim’s deep biological expertise, the collaboration is positioned to fast-track the development of transformative antibody drugs for unmet medical needs.